Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

Benzinga_recent_news02-11

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares are up on Tuesday’ as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762. The $9 million market cap ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610858622?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/10/3D-Illustration-Depicting-Cancer-Cells-I.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-02-11 00:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610858622","market":"sh","top_or_hot":-1,"title":"Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients","media":"Benzinga_recent_news","content":"<div>\n<p>Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares are up on Tuesday’ as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762.\nThe $9 million market cap ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50515549/cancer-biotech-phio-pharmaceuticals-stock-surges-as-trial-shows-tumor-clearance-at-highest-dose-in-skin-cancer-patients\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-11 00:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/02/50515549/cancer-biotech-phio-pharmaceuticals-stock-surges-as-trial-shows-tumor-clearance-at-highest-dose-in-skin-cancer-patients><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares are up on Tuesday’ as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762.\nThe $9 million market cap ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50515549/cancer-biotech-phio-pharmaceuticals-stock-surges-as-trial-shows-tumor-clearance-at-highest-dose-in-skin-cancer-patients\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMA","symbol_name":"Smartstop Self Storage REIT Inc","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/02/50515549/cancer-biotech-phio-pharmaceuticals-stock-surges-as-trial-shows-tumor-clearance-at-highest-dose-in-skin-cancer-patients","article_id":"2610858622","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/10/3D-Illustration-Depicting-Cancer-Cells-I.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/02/50515549/cancer-biotech-phio-pharmaceuticals-stock-surges-as-trial-shows-tumor-clearance-at-highest-dose-in-skin-cancer-patients","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610858622","pubTimestamp":1770739920,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its PH-762 skin cancer drug, with FDA talks planned in 2026.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMA":"Smartstop Self Storage REIT Inc","BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","PHIO":"Phio Pharmaceuticals","BK4139":"生物科技","BK4217":"自存仓储房地产信托"},"translate_title":"癌症生物技术Phio Pharmaceuticals股价飙升，试验显示皮肤癌患者在最高剂量下可清除肿瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHIO":1.5,"SMA":1,"LABU":1.5},"content_text":"Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares are up on Tuesday’ as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762.\nThe $9 million market cap biotech is surging with a session volume of 5.82 million compared to the average volume of 412.49 thousand, according to Benzinga Pro data.\nThe Safety Monitoring Committee concluded its review of the trial, reporting no serious adverse events or dose-limiting toxicities across all five dose escalation cohorts.\nNotably, the highest dose concentration yielded an 85% pathological response rate, with complete tumor clearance achieved in four out of six responders.\nA total of 22 patients with cutaneous carcinomas (type of skin cancer) completed treatment in the Phase 1b trial and underwent excision of the treated lesional site.\nThe patients completed 4 intratumoral injections of PH-762 and have been followed through at least 4 weeks after the final injection. PH-762 has been evaluated in patients within five dose-escalating cohorts, increasing drug concentration 20-fold from the first to the fifth and final cohort.\nWhile final study data is pending formal analysis, an FDA submission intended to propose and seek guidance for next steps in clinical study design for PH-762 is targeted for the second quarter of 2026.\nExperimental work and documentation for process and methods development, as well as impurities testing, are currently meeting expected timelines to commence manufacturing of cGMP material in the second half of 2026.\nAdditionally, the company is on track to have material available for non-human primate studies by March 2026, which is a prerequisite for commencing human pivotal trials. These developments underscore the potential of PH-762 as a non-surgical treatment for skin cancers.\nPhio Pharmaceuticals is currently trading 12.5% below its 20-day simple moving average (SMA) and 17.3% below its 50-day SMA, reflecting a bearish trend in the short to medium term. Over the past 12 months, shares have decreased by approximately 49.44%, and the stock is positioned closer to its 52-week lows than its highs, indicating ongoing challenges.\nThe RSI is at 34.74, which is considered neutral territory, while the MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum for the stock.\nPHIO Price Action: Phio Pharma shares were up 51.11% at $1.36 at the time of publication on Tuesday, according to Benzinga Pro data.\nImage by Aunt Spray via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610858622","isCrawlerRequest":true}